VCELVericel Corporation

Healthcare

$42.51+22% 1Y

$42.51

$29.3452 weeks$48.31

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but rich vs its sector.

1 good, 1 to watch, 1 without data

What the price assumes~+13% a year

Priced for ~13% a year FCF growth. The price demands less than its three-year revenue growth of 20% a year, expectations look modest.

Vs sector (EV/EBIT)111.8×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

All from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)bottom 6% of the market

FCF yieldbehind 77% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What VCEL's price assumes

Vericel Corporation trades at 90.5× earnings against 19.8× for the median Biotechnology name, more expensive than its own group.

90.5

Trailing P/E · Biotechnology median 19.8 · 4.57× the median: the market pays up for this one

Price / sales: 7.11
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 2.8%
Free cash flow yield · Biotechnology median 4.3%
Growth the price implies: +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; the business has delivered +43% a year over the last three.